NEW HORIZON FOR TREATMENT IN
Nuovi farmaci per il trattamento delle IBD
Marina Aloi, Giulia Catassi
UOC di Gastroenterologia, Epatologia ed Endoscopia Digestiva Pediatrica Dipartimento Materno-Infantile e ScienzeUrologiche Università Sapienza di Roma, Ospedale Policlinico Umberto I
Over the last two decades, the development of biologic therapies has been spurred by a deeper comprehension of the various signaling pathways associated with IBD. These biologics have been game-changers in setting therapeutic goals for children with IBD. Despite their transformative impact, a percentage of patients do not respond or lose response in time. In response to these challenges, there’s a wave of emerging therapies targeting specific pathogenetic mechanisms. These therapies, which include JAK inhibitors, anti-IL-23 antibodies, sphingosine-1-phosphate receptor modulators, anti-integrin therapies, and other small molecules, have demonstrated promising efficacy and safety in preliminary clinical trials. Nevertheless, despite recent approvals for new drugs to treat adults with inflammatory bowel disease (IBD), there are only two approved treatment options (infliximab and adalimumab) for children with IBD. This review aims to shed light on the clinical trial data available for these nascent drugs, signaling hope for more effective and safer treatment alternatives for pediatric IBD in the near future.